Business
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected "VIVI Cap Smart" deviceVancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution...
About this update from Tempramed Technologies Ltd.
[{"type":"text","content":"Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected "VIVI Cap Smart" device","length":156,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea.","length":393,"tagName":"p"},{"type":"text","content":"The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–based healthcare distribution company (www.mavens.kr), marks another step forward in TempraMed's growth across Asia and follows the recent granting of a South Korean patent protecting its proprietary thermal-insulation technology. Mavens brings established relationships across the South Korean healthcare ecosystem, supporting continued market expansion and access to patients and care providers nationwide.","length":498,"tagName":"p"},{"type":"text","content":"South Korea represents one of the region's fastest-growing markets for injectable therapies, supported by a robust pharmaceutical industry. The country's pharmaceutical market is one of the largest in Asia, with revenues expected to grow significantly over the next decade.","length":281,"tagName":"p"},{"type":"text","content":"Within this broader market, diabetes medications — including insulin and newer non-insulin injectables — show strong demand. The South Korean diabetes drugs sector alone is valued at nearly US$1 Bn and is projected to continue growing as the prevalence of diabetes rises with aging and lifestyle shifts1.","length":304,"tagName":"p"},{"type":"text","content":"As patients increasingly rely on temperature-sensitive therapies such as insulin, GLP-1 receptor agonists, biologics, and emergency injectables, protecting these medications from heat, cold, and environmental extremes becomes critical. Heat and cold exposure can degrade potency and jeopardize treatment effectiveness, highlighting the importance of reliable passive thermal protection in everyday life.","le...